ERBB2 and neoplasm: When adjusting for treatment and other tumor characteristics, including tumor size, PgR and HER2, the statistical significance for GATA3 was lost (HR = 0.81, 95% CI 0.50–1.31, p = 0.39), whereas tumor size (>20 mm vs ≤20 mm; HR = 2.16, 95% CI 1.39–3.36, p = 0.00067) and tamoxifen (HR = 0.45, 95% CI 0.30–0.67, p < 0.0001) were significant.